StreetAlpha.app
Home › Stocks › CING

Cingulate Inc. (CING)

Healthcare
$4.51
▼ −14.26%
LAST CLOSE · NOV 20

Cingulate develops once-a-day ADHD and anxiety medicines using its proprietary drug delivery platform. It last closed at $4.51 on Nov 20, down 14.26% on the day. The next earnings report for CING is expected around Wed, Mar 17, 2027. For the quarter ended Sep 2026, CING reported EPS of -$0.53. Over its last 8 reports the stock moved an average of 10.8% the session after earnings. Over the last 12 months CING insiders bought $657K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is CING in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CING.

Key Stats

Last 12 months
Results
Net income
−$29.2M
EPS (diluted)
−$2.67
Free cash flow
−$24.2M
Valuation
Market cap
$67.5M
15.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$23.2M
At Sep 30
Shareholder equity
$20.8M
Shares outstanding
15.0M
At Nov 13
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $99K$99KFY2024FY2025: −$1.4M−$1.4MFY2025

From CING's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Mar 17
Estimated date · Time not announced
Reported EPS
-$0.53
Quarter ended Sep 2026
Year ago EPS
-$1.35
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.17Dec '24Mar 2025: -$1.06Mar '25Jun 2025: -$1.14Jun '25Sep 2025: -$1.35Sep '25Dec 2025: -$0.84Dec '25Mar 2026: -$0.95Mar '26Jun 2026: -$0.45Jun '26Sep 2026: -$0.53Sep '26Latest -$0.53
Revenue by quarter
Not enough quarters on file yet.
How CING moved after its last 8 reports
Average move the session after a report ±10.8%
Nov 13, 2026After the close−12.8%
Aug 13, 2026Time not announced−4.2%
May 14, 2026Time not announced−10.8%
Mar 18, 2026Time not announced−31.1%
Nov 13, 2025Time not announced−12.4%
Aug 19, 2025Time not announced−9.6%
May 8, 2025After the close−2.0%
Mar 26, 2025Time not announced+3.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CINGStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CING
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CING

Technical Analysis

CING · as of the Nov 20 close · updated each morning
Downtrend

The stock is 5% below its 20 day and 7% below its 50 day average. It is 19% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 47). The nearest support is the swing low (Jul 28) at $4.25, and the nearest resistance the Pivot at $4.72.

Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 9.9%/day
Key levels
$11.8952 week high+163.6%
$5.35200 day average+18.6%
$5.03Pivot R1+11.5%
$4.92100 day average+9.1%
$4.84Swing high (Nov 10)+7.3%
$4.8150 day average+6.7%
$4.7420 day average+5.1%
$4.72Pivot+4.7%
$4.51Last close
$4.25Swing low (Jul 28)−5.8%
$4.19Pivot S1−7.1%
$3.1652 week low−29.9%
Indicators
RSI (14)47.31Middle of its rangeNeutral
MACD-0.04Above its signal lineBullish
Stochastic71.4Middle of its rangeNeutral
ADX (14)16.3No clear trend
Williams %R-53.2Oversold below −80, overbought above −20Neutral
CCI (20)-6.5Oversold below −100, overbought above 100Neutral
Rate of change+5.9%Change over 10 sessionsBullish
ATR (14)$0.45Typical daily range, 9.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CING

What happened before

See how CING did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CING usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CING has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CINGHow many large options trades hit CING, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CING Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲29 buying vs 9 selling
  • ▲Held by funds +5.9 pts
  • ▲Funds holding +8
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4234+23.5%
In funds' top 1000–
Held by funds19.1%13.2%+5.9 pts
New / increased14 / 1510 / 16+11.5%
Reduced / sold out3 / 64 / 4+12.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CING institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CING Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$657K5 buys · 5 insiders
Sold$00 sales · 0 insiders
Cluster buy: 5 insiders bought $657K between Feb 6 and Feb 13.
2026-02 bought $657KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Feb 13Thomas Jeffrey HargrovesDirectorBuy97,276$5.04$490K
Feb 6Matthew BramsEVP and Chief Medical OfficerBuy1,946$5.04$10K
Feb 6Shane J. SchafferCEOBuy6,809$5.04$34K
Feb 6Jennifer L. CallahanSVP and CFOBuy4,864$5.04$25K
Feb 6Peter J. WerthDirectorBuy19,455$5.04$98K
Every insider buy and sale for CING over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CING insider trades →

From SEC Form 4 filings by CING's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CING is in one of them and how their past CING trades turned out.

CING in the AI portfolios
Loading…

CING News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CING in an article yet. Here's the latest on the wider market.

CING in the news

About Cingulate

Cingulate is a biopharmaceutical company based in Kansas City, Kansas. It uses its proprietary Precision Timed Release drug delivery platform to develop medicines that release doses at set times, so patients can take them one time a day. Its lead candidate, CTx-1301, is a stimulant for attention deficit hyperactivity disorder and is under review by the U.S. Food and Drug Administration. The company is also developing a buspirone tablet for anxiety, with patients, physicians and payers as its intended users.

Headquarters
Kansas City, KS